Étiquette : anxiété

Review of Sacred Knowledge : Psychedelics and Religious Experience, William A. Richards, 2016

Review of Sacred Knowledge : Psychedelics and Religious Experience William A. Richards New York, NY: Columbia University Press, 2016. 269 pp. ISBN 978-0-231-17406-0 $29.95 Reviewed by Michael J. Winkelman http://dx.doi.org/10.1037/a0040299   Abstract Reviews the book, Sacred knowledge: Psychedelics and religious experiences, by William A. Richards. Richards’s career of clinical research with psychedelics and professional formation in theology, comparative religion and the psychology of religion bring integrative perspectives to understanding psychedelic experiences. Clinical accounts, scientific research and his personal experiences with psychedelics enable Richards to address issues of core importance in religious studies, medicine and society in general. Clinical studies with psychedelics provide findings that contribute to assessment of [...]

Lire la suite

Opportunities for cannabis in supportive care in cancer, Amber S. Kleckner et al., 2019

Opportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 DOI: 10.1177/1758835919866362   Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review was [...]

Lire la suite

Psychedelics, David E. Nichols, 2016

Psychedelics David E. Nichols Pharmacological Review, 2016, 68, 264–355 http://dx.doi.org/10.1124/pr.115.011478   Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .. . . .266 I. Introduction . . . . . . . . . . . . . . . . . . . . . . . [...]

Lire la suite

Priority Considerations for Medicinal Cannabis-Related Research, Marcel O. Bonn-Miller et al.,

Priority Considerations for Medicinal Cannabis-Related Research Marcel O. Bonn-Miller, Charles V. Pollack, Jr., David Casarett, Richard Dart, Mahmoud ElSohly, Larry Good, Manuel Guzman, Lumır Hanus, Kevin P. Hill, Marilyn A. Huestis, Eric Marsh, Susan Sisley, Nancy Skinner, Judith Spahr, Ryan Vandrey, Eugene Viscusi, Mark A. Ware, and Donald Abrams Cannabis and Cannabinoid Research, 2019, Volume 4, Number 3, 1-19. DOI: 10.1089/can.2019.0045   Keywords : medicinal cannabis; medical marijuana   Introduction and Rationale The National Academy of Sciences, Engineering, and Medicine’s 2017 publication The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research provided a significant contribution by synthesizing the existing evidence base [...]

Lire la suite

Psychedelic drugs in the treatment of anxiety, depression and addiction, Tor-Morten  KVAM et al., 2018

Psychedelic drugs in the treatment of anxiety, depression and addiction Tor-Morten  KVAM, Lowan H. STEWART, Ole A. ANDREASSEN  Tidsskrift for Den norske legeforening, 2018. Doi : 10.4045/tidsskr.17.1110   B A C K G R O U N D There is growing interest in the use of psychedelic drugs for the treatment of mental disorders. The drugs are considered safe when administered within a clinical framework. Older studies performed prior to 1970 had methodological shortcomings, but studies in recent years have shown promising results regarding the use of psychedelic drugs in unipolar depression, depression in life-threatening illness, anxiety and addiction. The aim of this literature review is [...]

Lire la suite

Clinical potential of psilocybine as a treatment for mental health conditions, Jeremy Daniel & Margaret Haberman, 2017.

Clinical potential of psilocybine as a treatment for mental health conditions Jeremy Daniel & Margaret Haberman Mental Health Clinician, 2017, Vol. 7, No. 1, pp. 24-28 https://doi.org/10.9740/mhc.2017.01.024   Abstract Psilocybin, a classic hallucinogen, is a chemical produced by more than 100 species of mushrooms worldwide. It has high affinity for several serotonin receptors, including 5-HT1A, 5-HT2A, and 5-HT2C, located in numerous areas of the brain, including the cerebral cortex and thalamus. With legislation introduced in 1992, more work is being done to further understand the implications of psilocybin use in a number of disease states. Certain mental health disease states and symptoms have been studied, including [...]

Lire la suite

The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study, Nadav Shalita et al., 2019

The association between cannabis use and psychiatric comorbidity in people with personality disorders : A population-based longitudinal study Nadav Shalita, Jürgen Rehmb, Shaul Lev-Ran Psychiatry Research, 2019, 278, 70–77 https://doi.org/10.1016/j.psychres.2019.05.041 A B S T R A C T Both personality disorders (PD) and cannabis use are highly comorbid with various psychiatric disorders. While previous research indicates specific interactions between cannabis use and schizotypal PD associated with schizophrenia, research into cannabis use among individuals with other PDs and the development of several additional psychiatric disorders is scarce. We explored the prevalence and incidence of psychiatric disorders among individuals with PDs who use cannabis, and whether individuals [...]

Lire la suite

Consideration of Ayahuasca for the Treatment of Posttraumatic Stress Disorder, Jessica L. NIELSON, & Julie D. MEGLER, 2012

Consideration of Ayahuasca for the Treatment of Post-traumatic Stress Disorder Jessica L. NIELSON, & Julie D. MEGLER MAPS Bulletin Annual Report, Winter 2012, 29-31.   THERE IS A GROWING AMOUNT OF RESEARCH on the development of PTSD and its various treatments. The fact that many people who su!er from PTSD struggle with the currently approved therapeutic options that are available to them suggests that we need to start exploring alternative strategies to treat this disorder.1 With the large number of veterans returning home from war that may have or will develop PTSD, we must have a diverse framework of therapy and integration in place [...]

Lire la suite

Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia, Berit Brogaard & Dimitria Electra Gatz, 2016

Psilocybin, Lysergic Acid Diethylamide, Mescaline, and Drug-Induced Synesthesia Berit Brogaard, Dimitria Electra Gatzia Neuropathology of Drug Addictions and Substance Misuse, 2016, Volume 2, chapter 83, 890-905. http://dx.doi.org/10.1016/B978-0-12-800212-4.00083-2 Copyright © 2016 Elsevier Inc. All rights reserved   INTRODUCTION Synesthesia typically involves either the stimulation of one sensory modality giving rise to an experience in a different sensory modality (such as when a smell or taste gives rise to a color experience) or the stimulation of a single sensory modality giving rise to an unusual qualitative experience (such as when an achromatic grapheme appears colored) (Baron-Cohen, Wyke, & Binnie, 1987; Brogaard, 2012; Cytowic, 1989; Day, 2005; Rich & Mattingley, [...]

Lire la suite

Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditionning, Briony J. Catlow et al., 2013

Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditionning CATLOW B.J., SONG S., PAREDES D.A., KIRSTEIN C.L., SANCHEZ-RAMOS J. Experimental Brain Research, 2013, 228, 481-491. Doi : 10.1007/s00221-013-3579-0   Abstract Drugs that modulate serotonin (5-HT) synaptic concentrations impact neurogenesis and hippocampal (HPC)-dependent learning. The primary objective is to determine the extent to which psilocybin (PSOP) modulates neurogenesis and thereby affects acquisition and extinction of HPC-dependent trace fear conditioning. PSOP, the 5-HT2A agonist 25I-NBMeO and the 5-HT2A/C antagonist ketanserin were administered via an acute intraperitoneal injection to mice. Trace fear conditioning was measured as the amount of time spent immobile in the presence of the conditioned [...]

Lire la suite